A field with a liver measles-mumps-rubella vaccine

Three lots of Lirutrin (measles-mumps-rubella live, attenuated virus vaccine) were evaluated in a double-blind, placebo-controlled clinical study involoving 273 children. The vaccine consisted of a combination of Schwarz strain measles, Jeryl Lynn strain mumps, and Cendehill strain rubella vaccine viruses. The frequency of positive clinical findings was essentially the same in susceptiable vaccinees, immune vaccinees, and placebo recipients; indicating that the observed symptoms were not caused by the vaccine. Antibody assay of paired serum samples revealed that measles, mumps, and rubella seroconverison rates in triple susceptible vaccinees were excellent, ranging from 96 to 98 per cent with all three lots combined. Results of this study show that Lirutrin trivalent vaccine is well tolerated and highly effective.